Photosensitizing antihypertensive medication and risk of skin cancer among postmenopausal women

Abstract

SummaryBackgroundFew prospective studies exist with an evaluation of a dose‐response relationship between use of some photosensitizing antihypertensive medications and skin cancer.Patient and MethodsWe used prospective data from the Women's Health Initiative Observational Study to investigate the association between antihypertensive use and risk of non‐melanoma skin cancer (NMSC) and melanoma in postmenopausal women aged 50–79 years at baseline (n  =  64,918). Multivariable Cox proportional hazards regression models were used and hazard ratios (HRs) and 95 confidence intervals (CIs) were calculated.Results8,777 NMSC and 1,227 melanoma cases were observed. Use of antihypertensives (HR [95% CI]: 1.12 [1.07–1.18]), ACE inhibitors (1.09 [1.01–1.18]), calcium channel blockers (1.13 [1.05–1.22]), diuretics (1.20 [1.12–1.27]), loop diuretics (1.17 [1.07–1.28]), and thiazides (1.17 [1.03–1.33]) were each associated with higher NMSC risk. NMSC risk linearly increased with use of multiple antihypertensives (p‐trend  =  0.02) and with longer duration of use (p‐trend < 0.01). Antihypertensives (1.15 [1.00–1.31]), angiotensin‐II receptor blockers (1.82 [1.05–3.15]), and diuretics (1.34 [1.13–1.59]) were each associated with elevated melanoma risk. Effect modification by solar radiation exposure was found between antihypertensive use and incidence of melanoma (p‐interaction  =  0.02).ConclusionsUse of antihypertensives overall, and several individual classes thereof, were associated with higher incidence of NMSC and melanoma with dose‐response relationship.